• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1995년도 제3회 추계심포지움
• /
• pp.101-106
• /
• 1995

• 한국식물병리학회:학술대회논문집
• /
• 한국식물병리학회 2002년도 총회 및 추계학술발표회
• /
• pp.55.1-55
• /
• 2002

• 한국식물병리학회:학술대회논문집
• /
• 한국식물병리학회 2002년도 총회 및 추계학술발표회
• /
• pp.54.2-55
• /
• 2002

• Korean Circulation Journal
• /
• 제54권4호
• /
• pp.221-222
• /
• 2024

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권2호
• /
• pp.539-543
• /
• 2016

Background: It is well known that peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is associated with a poor prognosis. However, data on the prognostic significance of modern chemotherapy containing bevacizumab, cetuximab or panitumumab are not available. Materials and Methods: This retrospective review concerned 526 patients with metastatic CRC who were classified into two groups according to the presence or absence of PC, and were treated with systemic chemotherapy, with or without bevacizumab or anti-EGFR antibodies. The genetic background, in particular KRAS, BRAF, and PIK3CA gene mutations, and overall survival (OS) were compared between the two groups. Results: The median OS values were 23.3 and 29.1 months for PC and non-PC patients, respectively (hazard ratio [HR]=1.20; p=0.17). Among all patients, tumor location, number of metastatic sites and BRAF mutation status were significant prognostic factors, whereas the presence of PC was not. In the PC group, chemotherapy with bevacizumab resulted in a significantly longer OS than forchemotherapy without bevacizumab (HR=0.38, p<0.01), but this was not the case in the non-PC group (HR=0.80, p=0.10). Furthermore, the incidence of the BRAF V600E mutation was significantly higher in PC than in non-PC patients (27.7% versus 7.3%, p<0.01). BRAF mutations displayed a strong correlation with shorter OS in non-PC (HR=2.26), but not PC patients (HR=1.04). Conclusions: Systemic chemotherapy, especially when combined with bevacizumab, improved survival in patients with PC from CRC as well as non-PC patients. While BRAF mutation demonstrated a high frequency in PC patients, but it was not associated with prognosis.

• Tuberculosis and Respiratory Diseases
• /
• 제52권1호
• /
• pp.76-85
• /
• 2002

BALT 림프종은 대부분 비호지킨스 림프종의 저등급의 B-세포 림프종으로서 쇼그렌씨 증후군 및 류마티스 관절염 등과 같은 자가면역질환과 관계가 있다고 알려져 있으나 전신성 홍반성 낭창에서 BALT 림프종의 발생에 대한 보고는 없는 것 같다. 저자들은 흉막성 통증을 주소로 내원한 54세 남자환자에서 전신성 홍반성 낭창으로 인한 흉막염의 원인규명과정에서 진단된 BALT 림프종에 대하여 문헌고찰과 함께 보고하는 바이다.

• Clinical and Experimental Pediatrics
• /
• 제49권8호
• /
• pp.895-897
• /
• 2006

폐 격리증이 없는 정상적인 폐에 체 혈관이 이상 기시하는 것은 매우 드문 질환이다. 저자들은 반복적인 하기도 감염을 보이는 영아에서 선천성 심장질환의 상태가 본 하기도 감염을 나타낼 정도로 심하지 않음을 이상히 여겨 컴퓨터 단층 촬영을 시행하였다. 그 결과 폐 격리증이 없는 폐의 이상 체 동맥 기시가 우측 폐하 엽에 존재함과 동시에 우측 하엽 폐동맥이 없는 사실을 확인하게 되었다. 어린 나이에 이 같은 선천성 질환의 조합은 이전에 보고 된 바가 없는 매우 드문 질환으로 생각된다.

• Journal of Yeungnam Medical Science
• /
• 제40권4호
• /
• pp.435-441
• /
• 2023

Pheochromocytomas and paragangliomas (PPGLs) may secrete hormones or bioactive neuropeptides such as interleukin-6 (IL-6), which can mask the clinical manifestations of catecholamine hypersecretion. We report the case of a patient with delayed diagnosis of paraganglioma due to the development of IL-6-mediated systemic inflammatory response syndrome (SIRS). A 58-year-old woman presented with dyspnea and flank pain accompanied by SIRS and acute cardiac, kidney, and liver injuries. A left paravertebral mass was incidentally observed on abdominal computed tomography (CT). Biochemical tests revealed increased 24-hour urinary metanephrine (2.12 mg/day), plasma norepinephrine (1,588 pg/mL), plasma normetanephrine (2.27 nmol/L), and IL-6 (16.5 pg/mL) levels. ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/CT showed increased uptake of FDG in the left paravertebral mass without metastases. The patient was finally diagnosed with functional paraganglioma crisis. The precipitating factor was unclear, but phendimetrazine tartrate, a norepinephrine-dopamine release drug that the patient regularly took, might have stimulated the paraganglioma. The patient's body temperature and blood pressure were well controlled after alpha-blocker administration, and the retroperitoneal mass was surgically resected successfully. After surgery, the patient's inflammatory, cardiac, renal, and hepatic biomarkers and catecholamine levels improved. In conclusion, our report emphasizes the importance of IL-6-producing PPGLs in the differential diagnosis of SIRS.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.10.1-10.17
• /
• 2022

Systemic autoimmune diseases arise from loss of self-tolerance and immune homeostasis between effector and regulator functions. There are many therapeutic modalities for autoimmune diseases ranging from conventional disease-modifying anti-rheumatic drugs and immunosuppressants exerting nonspecific immune suppression to targeted agents including biologic agents and small molecule inhibitors aiming at specific cytokines and intracellular signal pathways. However, such current therapeutic strategies can rarely induce recovery of immune tolerance in autoimmune disease patients. To overcome limitations of conventional treatment modalities, novel approaches using specific cell populations with immune-regulatory properties have been attempted to attenuate autoimmunity. Recently progressed biotechnologies enable sufficient in vitro expansion and proper manipulation of such 'tolerogenic' cell populations to be considered for clinical application. We introduce 3 representative cell types with immunosuppressive features, including mesenchymal stromal cells, Tregs, and myeloid-derived suppressor cells. Their cellular definitions, characteristics, mechanisms of immune regulation, and recent data about preclinical and clinical studies in systemic autoimmune diseases are reviewed here. Challenges and limitations of each cell therapy are also addressed.

• 한국토양비료학회지
• /
• 제35권4호
• /
• pp.223-231
• /
• 2002

인산가용 미생물인 Enterobacter intermedium 60-2G의 식물생장촉진 능력과 흑성병균인 Cladosporium cucumerinum에 대한 유도전신저항성 능력을 오이와 오이 흑성병균을 모델로 확인하였다. E. intermedium 을 처리한 오이는 물을 처리한 control에 비해 C. cucumerinum에 의한 흑성병의 병징이 현저히 감소하였다. 또한 E. intermedium를 처리한 오이는 식물 생장촉진효과도 보였다. Strain 60-2G은 Fusarium oxysporum와 Magnaporthe grisea을 포함한 여러 식물 병원 곰팡이에 대해 강한 항균활성을 나타내었다. 본 연구는 인산가용능력을 가진 E. intermedium 60-2G는 식물의 생육을 증진시키는데 관여하는 여러가지 유익한 형질을 가진 아주 유용한 생물적 방제균임을 밝혔다.